Immune checkpoint inhibitor resistance in soft tissue sarcoma

Abstract

The emergence of immunotherapy as a cancer therapy has dramatically changed the treatment paradigm of systemic cancer therapy. There have been several trials evaluating immune checkpoint blockade (ICI) in soft tissue sarcoma. While there is generally a limited response in sarcoma, a subset of patients has durable responses to immunotherapy. This is attributable to a variety of factors including histologic subtype, tumor-infiltrating lymphocytes, and the tumor microenvironment among others. There is ongoing translational and clinical research evaluating ICI resistance in sarcoma and identifying therapeutic strategies to overcome this resistance. Herein, we provide a review of the current data, proposed mechanisms of resistance, and potential approaches to overcome this resistance.

Keywords

Sarcoma / soft tissue sarcoma / checkpoint inhibitor / immunotherapy / resistance

References

[1] Brownstein JM.Malignant soft-tissue sarcomas.Hematol Oncol Clin North Am2020;34:161-75

[2] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[3] Italiano A,Cesne AL.Trends in survival for patients with metastatic soft-tissue sarcoma.Cancer2011;117:1049-54

[4] Ratan R.Chemotherapy for soft tissue sarcoma.Cancer2016;122:2952-60

[5] Pollack SM,Yearley JH.T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Cancer2017;123:3291-304 PMCID:PMC5568958

[6] Wisdom AJ,Riedel RF.Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.Cancer2018;124:3819-29 PMCID:PMC6215523

[7] Bui NQ,Hiniker SM.Contemporary management of metastatic soft tissue sarcoma.Curr Probl Cancer2019;43:289-99

[8] Judson I,Gelderblom H.Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol2014;15:415-23

[9] Meyer M.First-line therapy for metastatic soft tissue sarcoma.Curr Treat Options Oncol2019;20:6

[10] Ravi V,Benjamin RS.Chemotherapy for soft-tissue sarcomas.Oncology (Williston Park)2015;29:43-50

[11] Tap WD,Van Tine BA.Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.Lancet Oncol2017;18:1089-103 PMCID:PMC7771354

[12] Siozopoulou V,Zwaenepoel K.Immune checkpoint inhibitory therapy in sarcomas: is there light at the end of the tunnel?.Cancers (Basel)2021;13:360 PMCID:PMC7835811

[13] Tawbi HA,Bolejack V.Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol2017;18:1493-501 PMCID:PMC7939029

[14] D’angelo SP,Van Tine BA.Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol2018;19:416-26 PMCID:PMC6126546

[15] Wilky BA.Immune checkpoint inhibitors: The linchpins of modern immunotherapy.Immunol Rev2019;290:6-23

[16] Martin-Broto J,Grignani G.Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.J Immunother Cancer2020;8:e001561 PMCID:PMC7674086

[17] Pollack SM,Baker KK.Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial.JAMA Oncol2020;6:1778-82 PMCID:PMC7489365

[18] Kelly CM,Bowler T.Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical Trial.JAMA Oncol2020;6:402-8 PMCID:PMC6990941

[19] Gordon EM,Kim K.SAINT: results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].J Clin Oncol2022;38:11520

[20] Maki RG,Gnjatic S.A pilot study of anti-ctla4 antibody ipilimumab in patients with synovial sarcoma.Sarcoma2013;2013:168145 PMCID:PMC3608267

[21] Ben-Ami E,Solomon S.Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study.Cancer2017;123:3285-90 PMCID:PMC5762200

[22] Chen DS.Oncology meets immunology: the cancer-immunity cycle.Immunity2013;39:1-10

[23] Starzer AM,Hamacher R.Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.J Immunother Cancer2021;9:e001458 PMCID:PMC7993298

[24] Chalmers ZR,Fabrizio D.Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med2017;9:34 PMCID:PMC5395719

[25] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017;168:707-23 PMCID:PMC5391692

[26] Kalbasi A.Tumour-intrinsic resistance to immune checkpoint blockade.Nat Rev Immunol2020;20:25-39 PMCID:PMC8499690

[27] Wilky BA,Subhawong TK.Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.Lancet Oncol2019;20:837-48

[28] Keung EZ,Salazar R.Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab.Clin Cancer Res2020;26:1258-66 PMCID:PMC7731262

[29] D’Angelo SP,Agaram NP.Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.Hum Pathol2015;46:357-65 PMCID:PMC5505649

[30] Boxberg M,Lenze U.PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.Oncoimmunology2018;7:e1389366 PMCID:PMC5790346

[31] Italiano A,D’Angelo S.PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.J Hematol Oncol2020;13:55 PMCID:PMC7236113

[32] Lee CH,Vrijaldenhoven S.Prognostic significance of macrophage infiltration in leiomyosarcomas.Clin Cancer Res2008;14:1423-30

[33] Petitprez F,Keung EZ.B cells are associated with survival and immunotherapy response in sarcoma.Nature2020;577:556-60

[34] Matsushita H,Koboldt DC.Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.Nature2012;482:400-4 PMCID:PMC3874809

[35] Verdegaal EM,Visser M.Neoantigen landscape dynamics during human melanoma-T cell interactions.Nature2016;536:91-5

[36] Anagnostou V,Forde PM.Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer.Cancer Discov2017;7:264-76 PMCID:PMC5733805

[37] Zaretsky JM,Shin DS.Mutations associated with acquired resistance to pd-1 blockade in melanoma.N Engl J Med2016;375:819-29 PMCID:PMC5007206

[38] Park SJ,Shin K.Prognostic role of pre-treatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma.J Clin Oncol2020;38:e23537

[39] Jiang L,Situ D.Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma.Oncotarget2015;6:9542-50 PMCID:PMC4496237

[40] Weidema ME,Koelsche C.; PALGA Group. DNA methylation profiling identifies distinct clusters in angiosarcomas.Clin Cancer Res2020;26:93-100

[41] Lu J,Liao Z.The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma.Cancer Biol Med2021:0-0

[42] Pfirschke C,Rickelt S.Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy.Immunity2016;44:343-54 PMCID:PMC4758865

[43] Russell SJ.Oncolytic virotherapy: a contest between apples and oranges.Mol Ther2017;25:1107-16 PMCID:PMC5417845

[44] O’Sullivan Coyne G,Hu J.Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft-tissue sarcomas.Clin Cancer Res2022;28:279-88 PMCID:PMC8776602

[45] Marrari A,Bozzarelli S.Activity of regorafenib in advanced pretreated soft tissue sarcoma: results of a single-center phase II study.Medicine (Baltimore)2020;99:e20719 PMCID:PMC7328961

[46] van der Graaf WT,Chawla SP.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.The Lancet2012;379:1879-86

[47] Ocadlikova D,Broto JM.Sunitinib exerts.in vitro12:577766 PMCID:PMC7952316

[48] Paoluzzi L.Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review.JAMA Oncol2019;5:254-60

[49] George S,Maki RG.Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.J Clin Oncol2009;27:3154-60 PMCID:PMC2716937